Abivax Stock Aims for New Highs After Breaking Through 115 Euro Resistance

The Stock Breaks Through the 115.10 € Resistance and Advances Above Its Moving Averages

Abivax stock is up 2.29% at 116.00 € mid-session, bringing its weekly gain to 9.54%. The stock is among the top performers in the SBF 120, with the index up 0.16%. During the session, the stock broke through its previously identified resistance at 115.10 €, a level that has been tested several times since the quarterly report (Q1 2026 accounts were revealed on May 22). The price is now trading above its three moving averages, with a gap of 9.68% over the MM20 (105.76 €) and 23.54% over the MM200 (93.90 €). The RSI at 61 remains in the neutral zone despite the recent acceleration, leaving room before an overheating signal. The year-over-year performance remains exceptional, over 2000%, fueled by clinical advancements in olofazimod for ulcerative colitis.

Three Funds Maintain a Bearish Bet of 3.01% of the Capital on the Stock

According to reviewed declarations, the cumulative net short position on Abivax reaches 3.01% of the capital, spread across three funds. The level has increased by 0.30 points over thirty days, indicating a slight intensification of the bearish bet without constituting a massive movement of defiance. This positioning signals that some institutional investors remain cautious or are covering exposure, despite the stock's rally. Operationally, the company has financial visibility until the fourth quarter of 2027, as communicated during the Q1 2026 earnings release (on May 22). The launch of a phase 3 ABTECT maintenance trial in ulcerative colitis is scheduled for the end of the second quarter of 2026. With the intra-session crossing of the 115.10 € resistance, the next technical level to watch is the recent highs recorded at the end of May, around 118 €.